Cubist Systematic Strategies’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-46,167
| Closed | -$270K | – | 4760 |
|
|
2022
Q4 | $270K | Sell |
46,167
-26,901
| -37% | -$141K | ﹤0.01% | 3421 |
|
|
2022
Q3 | $490K | Sell |
73,068
-17,055
| -19% | -$103K | ﹤0.01% | 3176 |
|
|
2022
Q2 | $379K | Buy |
+90,123
| New | +$357K | ﹤0.01% | 3276 |
|
|
2022
Q1 | – | Sell |
-12,254
| Closed | -$39K | – | 3937 |
|
|
2021
Q4 | $39K | Buy |
+12,254
| New | +$40.8K | ﹤0.01% | 3335 |
|
|
2021
Q3 | – | Sell |
-12,452
| Closed | -$53K | – | 3269 |
|
|
2021
Q2 | $53K | Sell |
12,452
-25,699
| -67% | -$109K | ﹤0.01% | 2784 |
|
|
2021
Q1 | $190K | Buy |
38,151
+36,650
| +2,442% | +$296K | ﹤0.01% | 2494 |
|
|
2020
Q4 | $19K | Sell |
1,501
-1,316
| -47% | -$15K | ﹤0.01% | 2505 |
|
|
2020
Q3 | $28K | Buy |
2,817
+2,724
| +2,929% | +$26.8K | ﹤0.01% | 2403 |
|
|
2020
Q2 | $1K | Buy |
+93
| New | +$892 | ﹤0.01% | 2367 |
|
|
2019
Q3 | – | Sell |
-18,235
| Closed | -$219K | – | 2579 |
|
|
2019
Q2 | $219K | Buy |
18,235
+7,563
| +71% | +$81.3K | ﹤0.01% | 2007 |
|
|
2019
Q1 | $129K | Buy |
+10,672
| New | +$157K | ﹤0.01% | 1939 |
|
|
2018
Q1 | – | Sell |
-18,324
| Closed | -$474K | – | 2141 |
|
|
2017
Q4 | $474K | Buy |
18,324
+13,595
| +287% | +$274K | 0.03% | 940 |
|
|
2017
Q3 | $70K | Buy |
+4,729
| New | +$68.6K | ﹤0.01% | 1693 |
|
|
2016
Q4 | – | Sell |
-1,783
| Closed | -$18K | – | 1941 |
|
|
2016
Q3 | $18K | Buy |
1,783
+649
| +57% | +$7.09K | ﹤0.01% | 1623 |
|
|
2016
Q2 | $13K | Sell |
1,134
-1,804
| -61% | -$23K | ﹤0.01% | 1650 |
|
|
2016
Q1 | $40K | Buy |
+2,938
| New | +$42.3K | ﹤0.01% | 1491 |
|
|
2015
Q3 | – | Sell |
-5,486
| Closed | -$82K | – | 2064 |
|
|
2015
Q2 | $82K | Buy |
5,486
+5,402
| +6,431% | +$82.3K | ﹤0.01% | 1650 |
|
|
2015
Q1 | $1K | Sell |
84
-13,782
| -99% | -$192K | ﹤0.01% | 1865 |
|
|
2014
Q4 | $185K | Buy |
+13,866
| New | +$179K | 0.01% | 1543 |
|
Cubist Systematic Strategies's CNCE Position: Q1 2023 in Review
Cubist Systematic Strategies sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 46,167 shares — an estimated $270K sold.
Cubist Systematic Strategies first reported a position in CNCE in Q4 2014 and held it in 19 quarters. The position peaked at $490K in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Cubist Systematic Strategies reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Cubist Systematic Strategies sold 46,167 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $270K.
- Cubist Systematic Strategies first reported a position in Concert Pharmaceuticals, Inc. in Q4 2014 and held it in 19 quarters.
- Cubist Systematic Strategies's Concert Pharmaceuticals, Inc. position peaked at $490K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.